ESMO 2018
First-Line Avelumab-Axitinib Combo Increases PFS for Patients With Advanced RCC
First-line treatment combining the immune checkpoint blocker avelumab (Bavencio, EMD Serono/Pfizer) with the ...
JANUARY 24, 2019
Adding RT to ADT Beneficial in Newly Diagnosed Metastatic Prostate Cancer
Local radiation therapy (RT) improves overall survival (OS) by 32% in patients diagnosed with metastatic prostate ...
DECEMBER 24, 2018
Olaparib Extends PFS in Ovarian Cancer in SOLO-1 Clinical Trial
Maintenance therapy with olaparib can reduce the risk for ovarian cancer disease progression and related death by ...
NOVEMBER 27, 2018
AEs From Esophagogastric Cancer Rx Are More Common in Women
Women are more prone to experience adverse effects (AEs) of esophagogastric cancer chemotherapy, according to ...
NOVEMBER 21, 2018
VR-CAP Beneficial in Transplant-Ineligible Untreated MCL Patients
Treatment with VR-CAP lengthens survival in patients with transplant-ineligible untreated mantle cell lymphoma ...
NOVEMBER 15, 2018
R-CHOP14 and 21 Equally Safe and Effective for DLBCL
Fourteen- and 21-day cycles of R-CHOP are similarly safe and effective in the treatment DLBCL, according data ...
NOVEMBER 15, 2018
